NVS
Novartis AGNYSEHealthcare$154.03-0.68%OpenMarket Cap: $297.32B
As of 2026-04-06
Valuation
P/E (TTM)
21.26
PEG
1.24
P/B
6.39
P/S
5.22
EV/EBITDA
14.02
DCF Value
$290.45
FCF Yield
5.7%
Div Yield
2.0%
Margins & Returns
Gross Margin
75.7%
Operating Margin
31.2%
Net Margin
24.9%
ROE
32.8%
ROA
23.1%
ROIC
16.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $13.33B | 73.4% | $3.52B | $2.41B | $1.25 | — |
| FY 2025 | $54.81B | 75.0% | $17.07B | $14.06B | $7.19 | $3.28 |
| Q3 2025 | $14.36B | 75.4% | $4.50B | $3.93B | $2.02 | — |
| Q2 2025 | $14.84B | 77.6% | $4.86B | $4.04B | $2.06 | — |
| Q1 2025 | $13.62B | 76.3% | $4.66B | $3.61B | $1.82 | $3.28 |
| Q4 2024 | $13.56B | 75.5% | $3.53B | $2.82B | $1.41 | — |
| FY 2024 | $51.72B | 75.2% | $14.54B | $11.94B | $5.87 | $3.20 |
| Q3 2024 | $13.17B | 75.4% | $3.63B | $3.19B | $1.57 | — |
| Q2 2024 | $12.87B | 75.3% | $4.01B | $3.25B | $1.59 | — |
| Q1 2024 | $12.12B | 74.5% | $3.37B | $2.69B | $1.31 | $3.20 |
| Q4 2023 | $11.78B | 74.3% | $2.58B | $8.48B | $4.11 | — |
| FY 2023 | $46.66B | 73.3% | $9.77B | $14.85B | $7.10 | $2.27 |